Sumitovant subsidiary Spirovant Sciences, which is developing inhaled gene therapies for the treatment of cystic fibrosis, has opened a new research laboratory and corporate headquarters in Philadelphia, PA, USA, the company said. Spirovant’s SP-101 inhaled adeno-associated virus (AAV) gene therapy for CF has been granted orphan disease and rare pediatric disease designations by the FDA. The company’s pipeline also includes SP-102, an inhaled lentivirus vector gene therapy for CF.
Spirovant CEO Joan Lau said, “Our growth and maturity as a leading gene therapy company have propelled us to expand into the new research facilities where we will redouble our efforts to develop promising treatments and cures for patients with respiratory diseases such as CF. Our diverse team of talented researchers and drug development professionals is committed to advancing promising drug candidates as a cornerstone of biotech innovation in Philadelphia.”
Read the Spirovant press release.
